

# CITATION REPORT

List of articles citing

Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants.

DOI: 10.1002/wps.20972

World Psychiatry, 2022, 21, 295-307.

**Source:** <https://exaly.com/paper-pdf/145309894/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| #  | Paper   | IF   | Citations |
|----|---|------|-----------|
| 16 | Continuing, reducing, switching, or stopping antipsychotics in individuals with schizophrenia-spectrum disorders who are clinically stable: a systematic review and network meta-analysis. <i>Lancet Psychiatry</i> , <b>2022</b> ,                                   | 23.3 | 1         |
| 15 | Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.   |      | 2         |
| 14 | Depicting Risperidone Safety Profiles in Clinical Trials Across Different Diagnoses Using a Dopamine D2-Based Pharmacological Class Effect Query Defined by FAERS.  |      | 0         |
| 13 | Modern possibilities of anti-relapse therapy of schizophrenia (experience with the use of aripiprazole). <b>2022</b> , 122, 63  |      | 0         |
| 12 | Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia. 1-12  |      | 0         |
| 11 | Paliperidone palmitate vs. paliperidone extended-release for the acute treatment of adults with schizophrenia: a systematic review and pairwise and network meta-analysis. <b>2022</b> , 12,  |      | 0         |
| 10 | Resting-State Brain Activity Dysfunctions in Schizophrenia and Their Associations with Negative Symptom Domains: An fMRI Study. <b>2023</b> , 13, 83  |      | 0         |
| 9  | Practical Guidance for the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia. Volume 15, 3915-3929   |      | 1         |
| 8  | Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST). <b>2023</b> ,  |      | 0         |
| 7  | Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM. Volume 19, 219-232   |      | 0         |
| 6  | High Rate of Discontinuation during Long-Acting Injectable Antipsychotic Treatment in Patients with Psychotic Disorders. <b>2023</b> , 11, 314  |      | 0         |
| 5  | Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics. <b>2023</b> , 322, 115138  |      | 0         |
| 4  | Safety of Antipsychotic Polypharmacy Versus Monotherapy in a Nationwide Cohort of 61,889 Patients With Schizophrenia.   |      | 0         |
| 3  | Effectiveness of SGA-LAIs on Clinical, Cognitive, and Social Domains in Schizophrenia: Results from a Prospective Naturalistic Study. <b>2023</b> , 13, 577   |      | 0         |
| 2  | Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study. Volume 19, 895-906 |      | 0         |
| 1  | Clinical trajectories of individuals with severe mental illness continuing and discontinuing long-acting antipsychotics: a one-year mirror-image analysis from the STAR Network Depot study. <b>2023</b> , 9,   |      | 0         |